Inhibition of PCSK9 in familial hypercholesterolaemia

被引：4
|
作者：
Sijbrands, Eric J. G. [1 ,2 ]
机构：
[1] Erasmus MC, Pharmacol Vasc & Metab Dis sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol & Internal Med, Cardiovasc Genet Sect, NL-3000 CA Rotterdam, Netherlands
来源：
LANCET | 2012年 / 380卷 / 9836期
关键词：
APOLIPOPROTEIN-B; CONTROLLED-TRIAL; LDL CHOLESTEROL; DOUBLE-BLIND; STATIN; ATHEROSCLEROSIS; MIPOMERSEN; EZETIMIBE; EFFICACY; THERAPY;
D O I：
10.1016/S0140-6736(12)60814-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [21] PCSK9 IN FAMILIAL HYPERCHOLESTEROLEMIA (FH)
    Lambert, G.
    Rye, K. -A.
    Burnett, J.
    Barter, P.
    Marais, D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 31 - 31
  • [22] PCSK9 inhibition in PAD
    Karina Huynh
    Nature Reviews Cardiology, 2018, 15 : 4 - 5
  • [23] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [24] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [25] Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
    Futema, Marta
    Plagnol, Vincent
    Li, KaWah
    Whittall, Ros A.
    Neil, H. Andrew W.
    Seed, Mary
    Bertolini, Stefano
    Calandra, Sebastiano
    Descamps, Olivier S.
    Graham, Colin A.
    Hegele, Robert A.
    Karpe, Fredrik
    Durst, Ronen
    Leitersdorf, Eran
    Lench, Nicholas
    Nair, Devaki R.
    Soran, Handrean
    Van Bockxmeer, Frank M.
    Humphries, Steve E.
    JOURNAL OF MEDICAL GENETICS, 2014, 51 (08) : 537 - 544
  • [26] THE VARIABLE EFFECT OF PCSK9 INHIBITION IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: EVIDENCE TO SUPPORT THE EXISTENCE OF ALTERNATIVE CHOLESTEROL LOWERING PATHWAYS
    Downie, Paul
    Gritzmacher, Lisa
    Palmer, Frances
    Bayly, Graham
    ATHEROSCLEROSIS, 2017, 263 : E42 - E42
  • [27] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [28] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
    Momtazi-Borojeni, Amir Abbas
    Banach, Maciej
    Ruscica, Massimiliano
    Sahebkar, Amirhossein
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208
  • [29] Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?
    Vuorio, Alpo
    Watts, Gerald F.
    Kovanen, Petri T.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1353 - 1356
  • [30] PCSK9 inhibitors for hypercholesterolaemia New drugs, old problems
    McGettigan, Patricia
    Ferner, Robin E.
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
12345